

OTC Pink Basic

Disclosure Guidelines

BIO TECH MEDICS, INC
BMCS SUMCOIN INDEX FUND (pending)
5850 CANOGA AVE, # 400, WOODLAND HILLS, CALIFORNIA 91367
800 988-3782
www.biotechmedics.com
tony@biotechmedics.com
SIC CODE: 8049

QUARTERLY REPORT

ENDING SEPTEMBER 30, 2021

As of SEPTEMBER 30, 2021, the number of shares outstanding of our Common Stock was:

202,356,178

As of JUNE 30, 2021, the number of shares outstanding of our Common Stock was:

202,356,178

As of DECEMBER 31, 2020, the number of shares outstanding of our Common Stock was:

202,356,178

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period: No: ☒

¹ "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

BIO TECH MEDICS, INC

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

WYOMING

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

NONE

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

NONE

The address(es) of the issuer's principal executive office:

5850 CANOGA AVE, #400, WOODLAND HILLS, CA. 91367

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address: ☒

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐ No: ☒

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

2) Security Information

Trading symbol:	<u>BMCS</u>
Exact title and class of securities outstanding:	<u>COMMON</u>
CUSIP:	<u>090699307</u>
Par or stated value:	<u>.001</u>

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

Total shares authorized: 500,000,000 as of date: 09/30/2021
Total shares outstanding: 202,356,178 as of date: 09/30/2021
Number of shares in the Public Float²: 38,501,178 as of date: 09/30/2021
Total number of shareholders of record: 4,700 as of date: 09/30/2021

All additional class(es) of publicly traded securities (if any):

Trading symbol: _____
Exact title and class of securities outstanding: _____
CUSIP: _____
Par or stated value: _____
Total shares authorized: _____ as of date: _____
Total shares outstanding: _____ as of date: _____

Transfer Agent

Name: TRANSFER ONLINE
Phone: 503.277.2950
Email: CAROLYN@TRANSFERONLINE.COM
Address: 512 SALMON ST, PORTLAND OREGON

Is the Transfer Agent registered under the Exchange Act?³ Yes: ☒ No: ☐

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☒

Shares Outstanding as of Second Most Recent Fiscal Year End: <u>Opening Balance</u> Date <u>12/31/19</u> Common: <u>202,356,178</u> Preferred: <u>0</u> Shares Outstanding as of Most Recent Fiscal Year End: <u>Opening Balance</u>	*Right-click the rows below and select "Insert" to add rows as needed.
--	--

² "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

³ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

Date <u>12/31/20</u> <u>202,356,178</u> Common: Preferred: <u>2,006,501</u>									
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
<u>9/19/2020</u>	<u>New</u>	<u>2M</u>	<u>Preferred</u>	<u>\$.001</u>	<u>No</u>	<u>Anthony Miller</u>	<u>Employment agreement</u>	<u>144</u>	<u>No</u>
<u>10/2/2020</u>	<u>New</u>	<u>6,501</u>	<u>Preferred</u>	<u>\$.001</u>	<u>No</u>	<u>David Adams-838, Daryl Bryant-600, So. Trust (Terrance Dolan)-563, Natasha Mercer-500, Rene Jaegr-2000, Lee Wilson-1500, Sandra Thomas-500</u>	<u>working capital</u>	<u>144</u>	<u>No</u>
<u>03/31/2021</u>	<u>New</u>	<u>6,109</u>	<u>Preferred</u>	<u>\$.01</u>	<u>No</u>	<u>Tamara Farrell-1500, Core Cons (Steven Cass)-3003, William Haramas-1000, David Adams-606</u>	<u>Working capital</u>	<u>144</u>	<u>No</u>
<u>06/30/2021</u> _____	<u>NEW</u>	<u>4,003</u>	<u>Preferred</u> _____	<u>\$.001</u>	<u>No</u>	<u>Stephanie Hirsch-3003, Scott Benson-1000,</u>	<u>Working capital</u>	<u>144</u>	<u>No</u> _____
<u>09/30/2021</u> _____	<u>NEW</u>	<u>600</u>	<u>Preferred</u> _____	<u>\$.001</u>	<u>No</u>	<u>Britt Wilson 600</u>	<u>Working capital</u>	<u>144</u>	<u>No</u> _____
Shares Outstanding on Date of This Report: Ending _____ Balance Ending Balance: Date <u>09/30/2021</u> <u>202,356,178</u> Common: Preferred: <u>2,037,213</u>									

Example: A company with a fiscal year end of December 31st, in addressing this item for its quarter ended September 30, 2020, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2018 through September 30, 2020 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

SEE ATTACHED

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ☒

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____

Use the space below to provide any additional details, including footnotes to the table above:

4) Financial Statements

A. The following financial statements were prepared in accordance with:

- ☒ U.S. GAAP
☐ IFRS

B. The financial statements for this reporting period were prepared by (name of individual)⁴:

Name: ANTHONY K. MILLER
Title: PRES/CEO
Relationship to Issuer: OFFICER

⁴ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance sheet;
- D. Statement of income;
- E. Statement of cash flows;
- F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- G. Financial notes; and
- H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

SEE ATTACHED

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

SEE ATTACHED

- B. Please list any subsidiaries, parents, or affiliated companies.

NONE

- C. Describe the issuers' principal products or services.

BioTech Medics, Inc. is a medical holding company that is engaged in provisional medical services that have a progressive business plan. The company has legacy patented technologies (for retail applications) that will be further developed and an even broader range of new products that will be disclosed throughout 2020 and beyond. Management has assembled an incredible team that will bring new and old products to the marketplace. The Company's divisions are Medical, Nutraceutical Products, Sports Medicine and Research & Development. These divisions all have products produced for their target audience.

6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

NONE

7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% of more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
<u>ANTHONY MILLER</u>	<u>PRES/CEO</u>	<u>LOS ANGELES CA</u>	<u>154M</u>	<u>COMMON PROXY</u>	<u>60+</u>	
<u>BCH MEDICS TRUST FRO KEITH HOUSER</u>	<u>69.3</u>	<u>154 M</u>	<u>COMMON</u>	<u>69.3</u>	<u>—</u>	<u>DECEASED</u>
<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>
<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>
<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>

8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

NONE

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

NONE

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

NONE

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

NONE

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

NONE

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name: THOMAS COOK
Firm: THE LAW OFFICES OF THOMAS C COOK
Address 1: 10470 W. CHEYENNE AVENUE, SUITE 115 PMB 303
Address 2: LAS VEGAS, NV 89129
Phone: 702-524-9151
Email: tccesq@aol.com

Accountant or Auditor

Name: Kristofer Heaton
Firm: Heaton & Company, PLLC
Address 1: 1438 N Highway 89 Ste120
Address 2: Farmington, UT 84025
Phone: 801-447-9572
Email: kris@heatoncpas.com

Investor Relations

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

Name: _____
Firm: _____
Nature of Services: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, ANTHONY K. MILLER certify that:

1. I have reviewed this SEPTEMBER 30, 2021, of BIO TECH MEDICS, INC.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

12/11/2021 [Date]

/S/ ANTHONY K. MILLER [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, ANTHONY K. MILLER certify that:

1. I have reviewed this SEPTEMBER 30, 2021, of BIO TECH MEDICS, INC.

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

11/12/2021 [Date]

/S/ ANTHONY K. MILLER [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

BIO TECH MEDICS, INC.
BALANCE SHEET
FOR THE QUARTER ENDED SEPTEMBER 30, 2021

	<u>Sep 30, 2021</u>
ASSETS	
Current Assets	
Cash	\$ 808
Total Current Assets	808
Fixed Assets	
Equipment	1,366,908
Furniture & Fixtures	372
Accumulated Depreciation	<u>(1,379,875)</u>
Total Fixed Assets, Net	(12,594)
Intangible Assets	
BioBody	5,000,000
US Patents SHBAN	1,250,000
Research & Development	15,250
Accumulated Amortization	<u>(6,250,000)</u>
Total Intangible Assets, Net	15,250
Other Assets	
Investment in Digital Currency	<u>30,000,000</u>
Total Other Assets	<u>30,000,000</u>
TOTAL ASSETS	<u><u>\$ 30,003,464</u></u>
LIABILITIES & STOCKHOLDERS' EQUITY	
Liabilities	
Current Liabilities	
Accounts Payable	\$ 9,400
Employment Accrual - Related Party	<u>247,796</u>
Total Current Liabilities	<u>257,196</u>
Total Liabilities	\$ 257,196
Stockholders' Equity	
Series A Preferred Stock - Par Value \$0.001	
5,000,000 authorized, 2,012,610 issued and outstanding	2,053
Common Stock - \$0.001 Par Value	
500,000,000 shares authorized,	202,356
202,356,178 shares issued and outstanding	
Additional Paid In Capital	30,991,518
Accumulated Deficit	<u>(1,449,660)</u>
Total Stockholders' Deficit	<u>29,746,267</u>
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY	<u><u>\$ 30,003,464</u></u>

The accompanying notes are an integral part of these financial statements

BIO TECH MEDICS, INC.
STATEMENT OF OPERATIONS
FOR THE QUARTER ENDED SEPTEMBER 30, 2021

	Sep 30, 2021
REVENUE	\$ -
EXPENSES	
Salaries & Wages - Related Party	30,000
General & Administrative	41,532
Total Expense	71,532
OTHER INCOME (EXPENSE)	
Gain on Settlement of Debt	-
Total Other Income (Expense)	-
NET INCOME (LOSS)	\$ (71,532)
Basic & Diluted Weighted Average Common Shares Outstanding	202,356,178
Basic & Diluted Loss Per Share	\$ (0.00)

The accompanying notes are an integral part of these financial statements

BIO TECH MEDICS, INC.
STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY
FOR THE QUARTER ENDED SEPTEMBER 30, 2021

	Common Stock		Preferred Stock		Paid In Capital	Accumulated Deficit	Total
	Shares	Amount	Shares	Amount			
Balance 12/31/20	<u>202,356,178</u>	<u>\$ 202,356</u>	<u>2,006,501</u>	<u>\$ 2,007</u>	<u>\$ 823,264</u>	<u>\$ (1,214,405)</u>	<u>\$ (186,778)</u>
Issued Preferred Stock for Cash			6,109	6	91,644		91,650
Net Loss						(69,264)	(69,264)
Balance 3/31/21	<u>202,356,178</u>	<u>202,356</u>	<u>2,012,610</u>	<u>2,013</u>	<u>914,908</u>	<u>(1,283,668)</u>	<u>(164,391)</u>
Issued Preferred Stock for Cash			24,003	40	30,066,610		30,066,650
Net Loss						(94,459)	(94,459)
Balance 6/30/21	<u>202,356,178</u>	<u>202,356</u>	<u>2,036,613</u>	<u>2,052</u>	<u>30,981,519</u>	<u>(1,378,127)</u>	<u>29,807,800</u>
Issued Preferred Stock for Cash			600	1	9,999		10,000
Net Loss						(71,532)	(71,532)
Balance 9/30/21	<u>202,356,178</u>	<u>202,356</u>	<u>2,037,213</u>	<u>2,053</u>	<u>30,991,518</u>	<u>(1,449,659)</u>	<u>29,746,268</u>

BIO TECH MEDICS, INC.
STATEMENT OF CASH FLOWS
FOR THE QUARTER ENDED SEPTEMBER 30, 2021

	<u>Sep 30, 2021</u>
OPERATING ACTIVITIES	
Net Loss	\$ (71,532)
Adjustments to reconcile net loss to net cash provided by (used in) operations:	
Gain on Settlement of Debt	
Accounts Payable	(4,800)
Employment Accrual - Related Party	<u>29,200</u>
Net cash provided by (used in) Operating Activities	<u>(47,132)</u>
INVESTING ACTIVITIES	
Purchase of Furniture & Fixtures	
Investment in Digital Currency	
Net cash provided by (used in) Investing Activities	<u>-</u>
FINANCING ACTIVITIES	
Proceeds from Issuance of Preferred Stock	<u>10,000</u>
Net cash provided by Financing Activities	<u>10,000</u>
 Net cash increase (decrease) for period	 (37,132)
 Cash at beginning of period	 37,939
 Cash at end of period	 <u>\$ 807</u>
 SUPPLEMENTAL CASH FLOW INFORMATION	
 Interest Paid	 \$ -
Income Taxes Paid	\$ -

The accompanying notes are an integral part of these financial statements

**Notes to Financial Statements
For the Quarter ended September 30, 2021**

NATURE OF OPERATIONS

NOTE: 1 - HISTORY OF COMPANY

Bio Tech Medics, Inc. (The Company) was formed on December 29, 1997 to operate as a property owner and/or management service. On December 7, 2004, the Company acquired Halo Laser BioTherapy, LLC via a reverse merger which focused on alternative medicine, nutraceuticals, alcohol free hand sanitizer and high-powered deep penetrating laser medical devices for the twenty-first century. On November 6, 2007, the Company submitted documents with the secretary of state in Nevada to change the Company's name to Bio Tech Medics, Inc. and continued with limited operations until 2019

On June 6, 2019, Anthony K. Miller was appointed as the new Chairman and CEO of Bio Tech Medics, Inc., a Wyoming corporation. On June 18, 2019, the Secretary of State amended the corporation's records to reflect the change of officers. Bio Tech Medics, Inc is a publicly traded company on the OTC Market and trades under the stock symbol BMCS.

Prior to November 2020, BioTech Medics, Inc. was engaged in provisional medical services. The Company currently is changing its operations into cryptocurrency. The name is officially changed with the Secretary of State in Wyoming and is pending with FINRA. The new name is **BMCS SUMCOIN INDEX FUND, INC.**

As of the date of this filing Management continues to answer question from FINRA related to this name change waiting and anticipating the final approval of this corporate action.

NOTE 2 – GOING CONCERN

The Company currently has limited working capital and has not completed its efforts to establish a stabilized source of revenue sufficient to cover operating costs over an extended period of time. These conditions raise substantial doubt about the Company's ability to continue as a going concern.

Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses. The Company intends to position itself to raise additional funds through the capital markets. In light of management's efforts, there are no assurances that the Company will be successful in this or any of its endeavors to become financially viable. As reflected in the financial statements, the Company has some working capital for the period ended September 30, 2021, and a loss from operations. The Company is working on raising significant capital that is non-dilutive to be able to execute its current business plan. The accompanying financial statements have been prepared by management assuming the Company will continue in its efforts.

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles.

Use of Accounting Estimates

Management is required to make estimates and assumptions during the preparation of the financial statements and accompanying notes in conformity with accounting principles generally accepted in the United States of America. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial

statements. They also affect the reported amounts of net income. Actual results could differ materially from these estimates and assumptions.

Cash and Cash Equivalents

The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.

Fixed Assets

Equipment is stated at cost, net of accumulated depreciation. The cost of equipment is depreciated using the straight-line method. We estimate that the useful life of equipment is 5 years. Expenditures for maintenance and repairs are charged to expense as incurred. Additions, major renewals, and replacements that increase the equipment's useful life are capitalized. Equipment sold or retired, together with the related accumulated depreciation is removed from the appropriated accounts and the resultant gain or loss is included in net income.

Digital Assets

Guidance on how to account for and audit digital assets under U.S. generally accepted accounting principles (GAAP) for nongovernmental entities and generally accepted auditing standards (GAAS), respectively. This guidance is intended for financial statement preparers and auditors with a fundamental knowledge of blockchain technology. For the purposes of this practice aid, digital assets are defined broadly as digital records that are made using cryptography for verification and security purposes, on a distributed ledger (referred to as a blockchain). The distributed ledger keeps a record of all transactions on a blockchain network. Digital assets, as defined herein, may be characterized by their ability to be used for a variety of purposes, including as a medium of exchange, as a representation to provide or access goods or services, or as a financing vehicle, such as a security, among other uses. The rights and obligations associated with digital assets vary significantly, as do the terms used to describe them. It is important to note that the accounting treatment for a digital asset will ultimately be driven by the specific terms, form, underlying rights, and obligations of the digital asset.

SUMCOIN IS DESCRIBED AS "THE WORLD'S FIRST CRYPTOGRAPHIC INDEX WHICH USES A PROOF-OF-WORK ALGORITHM TO UNLOCK COINS". (MINEABLE... JUST LIKE BITCOIN) • THE INDEX •SUMCOIN, OR THE "SUM" OF COINS MEANS THAT IT TRACKS ALL COINS IN NEAR REAL TIME FROM OVER 600 DIFFERENT DATA POINTS. SUMCOIN IS CONTINUOUSLY AGGREGATING AND FINDS WHAT THE CURRENT TOP 100 COINS ARE BY GLOBAL MARKET CAP. •THE "SUM" PRICE IS GENERATED USING ALGORITHM BASED ON THE MARKET FLUCTUATIONS OF THE TOP 100 COINS. • NOTE: IF THE CRYPTO MARKET GROWS, THE VALUE OF SUM GROWS, IF IT DROPS, THE VALUE OF SUM DROPS. HOWEVER, BECAUSE OF THE NUMBER OF COINS IN THE INDEX CALCULATION, THE PRICE CHANGES OF SUM TEND TO BE LESS DRASTIC THAN THAT OF OTHER COINS – WHOSE PRICE IS DETERMINED BY THE MARKET OF SUPPLY AND DEMAND ALONE •SUMCOIN IS FOR THOSE WHO WANT TO GAIN MAXIMUM EXPOSURE TO THE DIGITAL ASSET SPACE... BUT MAY ONLY WANT TO HOLD ONE COIN FOR SIMPLICITY.

Goodwill and Other Intangible Assets

The Company accounts for goodwill and other intangible assets in accordance with ASC 350, "*Intangibles - Goodwill and Other*". Intangible assets with an indefinite life, namely goodwill, are not amortized. Intangible assets with a definite life are amortized on a straight-line basis over their estimated useful lives of seventeen years. Intangible assets with indefinite lives will be tested for impairment annually and when an event occurs that would indicate that the carrying amount may be impaired.

Impairment of Assets

In accordance with ASC 350 "*Intangibles – Goodwill and Other*" and ASC 360 "*Property, Plant and Equipment*," long-lived assets, such as property and equipment, and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When factors indicate that the assets should be evaluated for possible impairment, the Company uses an estimate of related cash flows. A deficiency in these cash flows relative to the carrying amounts is an indication of the need for a write-down due to impairment. Losses on impairment are recognized by a charge to earnings.

Income Taxes

Income taxes are computed using the asset and liability method in accordance with ASC 740 “*Income Taxes*.” Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

Fair Value of Financial Instruments

The Company, in estimating its fair value disclosures for financial instruments, uses the following methods and assumptions: The carrying amounts reported in the balance sheet for cash, accounts receivable, accounts payable and accrued expenses approximate their fair value due to their relatively short maturity.

Basic Income (Loss) Per Share

The Company computes income (loss) per share in accordance with FASB ASC 260 “Earnings per Share.” Basic loss per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted income (loss) per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is antidilutive. There are potentially dilutive debt or equity instruments issued or outstanding as of September 30, 2021, upon conversion of preferred shares into common shares.

Recent Accounting Pronouncements

We have reviewed all the recently issued, but not yet effective, accounting pronouncements and we do not believe any of these pronouncements will have a material impact on the Company.

NOTE 4 – STOCKHOLDERS’ EQUITY

The Company has 500,000,000, \$0.001 par value shares of common stock authorized, and 202,356,178 common shares issued and outstanding as of September 30, 2021. During the period ended September 30, 2021, the Company has issued Series A preferred shares to certain shareholders for \$10,000 in cash to be used as working capital. Additionally, the Company also issued 20,000 Series A preferred shares for \$30 Million dollars of Sumcoin Digital Assets (39,370 coin) that are reflected on the Company’s Balance Sheet as Digital Assets (currency). As of September 30, 2021, the issued and outstanding Series A preferred shares was 2,037,213 and 0 series B. There are 10 million authorized preferred shares (par value .001) including 5 million Series A, and 5 million Series B shares. Management has the authority to set the rights powers and privileges to these shares.

NOTE 5- RELATED PARTY TRANSACTIONS

The employment agreement for Anthony Miller, Chief Executive Officer, entered into on June 27, 2019, comprises the balance of the employment accrual – related party. Mr. Miller is entitled to compensation of \$120,000 per year for a period of five years. The balance owed to Mr. Miller as of December 31, 2020 was \$175,572. As of September 30, 2021, the balance is \$247,796

NOTE 6 – INCOME TAXES

The Company adopted the provisions of uncertain tax positions as addressed in ASC 740 “Income Taxes” (“ASC 740”). As a result of the implementation of ASC 740, the Company recognized no increase in the liability for unrecognized tax benefits. As of September 30, 2021, the Company had net operating loss carry forwards of approximately \$1,449,689 that may be available to reduce future years’ taxable income in varying amounts. Future tax benefits which may arise as a result of these losses have not been recognized in these

financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carryforwards.

As of September 30, 2021, the valuation allowance was approximately \$ \$257,196. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all the deferred income tax assets will not be realized.

The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of September 30, 2021. All tax years since 2017 remain open for examination by taxing authorities.

The provision for Federal income tax consists of the following:

	December 31, 2020	December 31, 2019
Federal income tax benefit attributable to:		
Income tax benefit	\$ 23,030	12,894
Change in valuation allowance	(23,030)	(12,894)
Net provision for Federal income taxes	\$ -	-

The cumulative tax effect at the expected rate of 21% of significant items comprising our net deferred tax amount is as follows:

	December 31, 2020	December 31, 2019
Deferred tax asset attributable to:		
Net operating loss carryover	\$ 255,025	231,995
Less: valuation allowance	(255,025)	(231,995)
Net deferred tax asset	\$ -	-

The related deferred tax benefit on the above unutilized tax losses has a full valuation allowance not recognized against it as there is no certainty of its realization. Management has evaluated tax positions in accordance with ASC 740 and has not identified any significant tax positions, other than those disclosed.

NOTE 7 – GAIN ON SETTLEMENT OF DEBT

During the year ended December 31, 2020, the Company had an outstanding balance of \$54,558 with its transfer agent. The Company negotiated a settlement with the transfer agent and paid \$10,000 and the remaining \$44,558 was forgiven by the transfer agent and recorded as a gain on settlement of debt.

NOTE 8 – SUBSEQUENT EVENTS

In accordance with ASC 855 “*Subsequent Events*,” the Company has analyzed its operations subsequent to December 31, 2020, through the date these financial statements were issued and has determined that it has no material subsequent events requiring disclosure.